BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18313529)

  • 1. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography.
    Lin Z; Mechalakos J; Nehmeh S; Schoder H; Lee N; Humm J; Ling CC
    Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1219-28. PubMed ID: 18313529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.
    Lee NY; Mechalakos JG; Nehmeh S; Lin Z; Squire OD; Cai S; Chan K; Zanzonico PB; Greco C; Ling CC; Humm JL; Schöder H
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):2-13. PubMed ID: 17869020
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Qiu J; Lv B; Fu M; Wang X; Zheng X; Zhuo W
    Head Neck; 2017 Dec; 39(12):2519-2527. PubMed ID: 28963789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
    Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
    Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxia dose painting by numbers: a planning study.
    Thorwarth D; Eschmann SM; Paulsen F; Alber M
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):291-300. PubMed ID: 17448882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance.
    Hendrickson K; Phillips M; Smith W; Peterson L; Krohn K; Rajendran J
    Radiother Oncol; 2011 Dec; 101(3):369-75. PubMed ID: 21872957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxia imaging with [18F]-FMISO-PET for guided dose escalation with intensity-modulated radiotherapy in head-and-neck cancers.
    Henriques de Figueiredo B; Zacharatou C; Galland-Girodet S; Benech J; De Clermont-Gallerande H; Lamare F; Hatt M; Digue L; De Mones del Pujol E; Fernandez P
    Strahlenther Onkol; 2015 Mar; 191(3):217-24. PubMed ID: 25245468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The reoxygenation of hypoxia and the reduction of glucose metabolism in head and neck cancer by fractionated radiotherapy with intensity-modulated radiation therapy.
    Okamoto S; Shiga T; Yasuda K; Watanabe S; Hirata K; Nishijima KI; Magota K; Kasai K; Onimaru R; Tuchiya K; Kuge Y; Shirato H; Tamaki N
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2147-2154. PubMed ID: 27251644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A model of reoxygenation dynamics of head-and-neck tumors based on serial 18F-fluoromisonidazole positron emission tomography investigations.
    Thorwarth D; Eschmann SM; Paulsen F; Alber M
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):515-21. PubMed ID: 17398015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer.
    Nehmeh SA; Lee NY; Schröder H; Squire O; Zanzonico PB; Erdi YE; Greco C; Mageras G; Pham HS; Larson SM; Ling CC; Humm JL
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):235-42. PubMed ID: 18086391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
    Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
    Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
    Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
    Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer.
    Choi W; Lee SW; Park SH; Ryu JS; Oh SJ; Im KC; Choi EK; Kim JH; Jung SH; Kim S; Ahn SD
    Radiother Oncol; 2010 Nov; 97(2):176-82. PubMed ID: 20855118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
    Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
    Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensity modulated radiation therapy dose painting for localized prostate cancer using ¹¹C-choline positron emission tomography scans.
    Chang JH; Lim Joon D; Lee ST; Gong SJ; Anderson NJ; Scott AM; Davis ID; Clouston D; Bolton D; Hamilton CS; Khoo V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e691-6. PubMed ID: 22658218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual tracer evaluation of dynamic changes in intratumoral hypoxic and proliferative states after radiotherapy of human head and neck cancer xenografts using radiolabeled FMISO and FLT.
    Fatema CN; Zhao S; Zhao Y; Yu W; Nishijima K; Yasuda K; Kitagawa Y; Tamaki N; Kuge Y
    BMC Cancer; 2014 Sep; 14():692. PubMed ID: 25245041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [18F]fluoromisonidazole and a new PET system with semiconductor detectors and a depth of interaction system for intensity modulated radiation therapy for nasopharyngeal cancer.
    Yasuda K; Onimaru R; Okamoto S; Shiga T; Katoh N; Tsuchiya K; Suzuki R; Takeuchi W; Kuge Y; Tamaki N; Shirato H
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):142-7. PubMed ID: 22583608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.